Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-BCT-100 in Advanced Arginine Auxotrophic Solid Tumors
NCT02285101Phase 1Completed
- Sponsor
- Bio-Cancer Treatment International Limited
- Start
- Nov 2014
- Primary completion
- Feb 2019
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of arginase in melanoma and prostate adenocarcinoma (6 cohorts), sponsored by Bio-Cancer Treatment International Limited. Primary endpoints: Adverse Events at 13 weeks and Optimal Biological Dose at 13 weeks. Started Nov 2014; status: completed.
02
Drugs
arginase
03
Conditions
melanomaprostate adenocarcinoma
Beyond the preview
Go deeper on NCT02285101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02285101.